JP3966900B2 - Ｈｉｖ・ｔａｔトランス活性化を抑制するための化合物 - Google Patents

Ｈｉｖ・ｔａｔトランス活性化を抑制するための化合物 Download PDF

Info

Publication number
JP3966900B2
JP3966900B2 JP51184496A JP51184496A JP3966900B2 JP 3966900 B2 JP3966900 B2 JP 3966900B2 JP 51184496 A JP51184496 A JP 51184496A JP 51184496 A JP51184496 A JP 51184496A JP 3966900 B2 JP3966900 B2 JP 3966900B2
Authority
JP
Japan
Prior art keywords
seap
tat
hiv
dna
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP51184496A
Other languages
English (en)
Japanese (ja)
Other versions
JPH10509421A (ja
JPH10509421A5 (enExample
Inventor
ルー・チー フアン、
ジョン・エヌ グナブレー、
Original Assignee
ザ・ジョンズ・ホプキンス・ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ジョンズ・ホプキンス・ユニバーシティー filed Critical ザ・ジョンズ・ホプキンス・ユニバーシティー
Publication of JPH10509421A publication Critical patent/JPH10509421A/ja
Publication of JPH10509421A5 publication Critical patent/JPH10509421A5/ja
Application granted granted Critical
Publication of JP3966900B2 publication Critical patent/JP3966900B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
JP51184496A 1994-09-30 1995-09-22 Ｈｉｖ・ｔａｔトランス活性化を抑制するための化合物 Expired - Lifetime JP3966900B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/316,341 1994-09-30
US08/316,341 US6365787B1 (en) 1994-09-30 1994-09-30 Compounds for the suppression of HIV TAT transactivation
PCT/US1995/011779 WO1996010549A1 (en) 1994-09-30 1995-09-22 Compounds for the suppression of hiv tat transactivation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006184646A Division JP2006273869A (ja) 1994-09-30 2006-07-04 Ｈｉｖ・ｔａｔトランス活性化を抑制するための化合物

Publications (3)

Publication Number Publication Date
JPH10509421A JPH10509421A (ja) 1998-09-14
JPH10509421A5 JPH10509421A5 (enExample) 2005-03-10
JP3966900B2 true JP3966900B2 (ja) 2007-08-29

Family

ID=23228649

Family Applications (2)

Application Number Title Priority Date Filing Date
JP51184496A Expired - Lifetime JP3966900B2 (ja) 1994-09-30 1995-09-22 Ｈｉｖ・ｔａｔトランス活性化を抑制するための化合物
JP2006184646A Withdrawn JP2006273869A (ja) 1994-09-30 2006-07-04 Ｈｉｖ・ｔａｔトランス活性化を抑制するための化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006184646A Withdrawn JP2006273869A (ja) 1994-09-30 2006-07-04 Ｈｉｖ・ｔａｔトランス活性化を抑制するための化合物

Country Status (10)

Country Link
US (4) US6365787B1 (enExample)
EP (1) EP0783474B1 (enExample)
JP (2) JP3966900B2 (enExample)
CN (2) CN100413835C (enExample)
AT (1) ATE403635T1 (enExample)
AU (1) AU700481B2 (enExample)
CA (1) CA2200991C (enExample)
DE (1) DE69535804D1 (enExample)
ES (1) ES2312168T3 (enExample)
WO (1) WO1996010549A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365787B1 (en) * 1994-09-30 2002-04-02 The Johns Hopkins University Compounds for the suppression of HIV TAT transactivation
WO1999017609A1 (en) * 1997-10-07 1999-04-15 Larreacorp, Ltd. Nontoxic extract of larrea tridentata and method of making the same
US6608108B2 (en) * 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives
US20030219407A1 (en) 2002-05-15 2003-11-27 The Regents Of The University Of California RNA silencing in animals as an antiviral defense
US7728036B2 (en) * 2003-05-20 2010-06-01 Erimos Pharmaceuticals, Llc Methods for delivery of catecholic butanes for treatment of tumors
CN103585136A (zh) * 2003-05-20 2014-02-19 约翰霍普金斯大学 用于治疗肿瘤的邻苯二酚丁烷的释放的方法和组合物
US20060141029A1 (en) * 2003-05-20 2006-06-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of diseases
CN100440843C (zh) * 2004-05-12 2008-12-03 华为技术有限公司 一种环网及其业务实现方法
US8440648B2 (en) * 2004-07-20 2013-05-14 Erimos Pharmaceuticals Llc Methods and compositions for treatment of intraepithelial neoplasia
CN101150956B (zh) * 2005-01-27 2013-04-17 埃里莫斯医药品有限公司 用于注射入动物的包括ndga化合物的儿茶酚丁烷配方
WO2006081363A2 (en) * 2005-01-27 2006-08-03 Erimos Pharmaceuticals Llc Oral formulations for delivery of catecholic butanes including ndga compounds
KR20090006062A (ko) * 2006-02-23 2009-01-14 에리모스 파마슈티컬스 엘엘씨 인플루엔자 바이러스 감염의 치료 방법
EP2076252B1 (en) * 2006-10-02 2014-04-02 Erimos Pharmaceuticals LLC Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
US9067875B2 (en) 2006-10-02 2015-06-30 Erimos Pharmaceuticals Llc Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
HRP20161017T1 (hr) * 2007-05-11 2016-10-21 Convatec Technologies Inc. Ostomijski uređaj
US20100093872A1 (en) * 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
MX2011004824A (es) * 2008-11-07 2012-01-12 Triact Therapeutics Inc Uso de derivados de butano catecólico en terapia contra el cáncer.
EP2663574A4 (en) * 2011-01-10 2014-12-17 Scripps Research Inst RETRO VIRUS REPLICATION INHIBITORS
SG11201404542TA (en) * 2012-02-03 2014-10-30 Univ Johns Hopkins Compositions comprising ndga derivatives and sorafenib and their use in treatment of cancer
SG11201500397XA (en) * 2012-07-18 2015-03-30 Univ Johns Hopkins Methods for inhibition of bnip3 and prevention and treatment of ischemia reperfusion injury by tetra-o-methyl nordihydroguaiaretic acid
US9834575B2 (en) 2013-02-26 2017-12-05 Triact Therapeutics, Inc. Cancer therapy
EP3044593A4 (en) 2013-09-09 2017-05-17 Triact Therapeutics, Inc. Cancer therapy

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008294A (en) 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes
US5276060A (en) * 1979-06-19 1994-01-04 Block/Chemex, G.P. Methods of treating tumors with compositions of catecholic butanes
DE3009542A1 (de) 1980-03-13 1981-09-24 Henkel KGaA, 4000 Düsseldorf Desodorierende kosmetische zusammensetzungen
US4774229A (en) 1982-04-05 1988-09-27 Chemex Pharmaceuticals, Inc. Modification of plant extracts from zygophyllaceae and pharmaceutical use therefor
US4880637A (en) * 1985-02-11 1989-11-14 Chemex Pharmaceuticals, Inc. Compositions of catecholic butanes with zinc
FR2632956B2 (fr) * 1988-05-13 1991-07-12 Pasteur Institut Sondes a papillomavirus hpv49, hpv50, hpv54, hpv55; produits genetiquement et immunologiquement lies a ce papillomavirus hpv49, hpv50, hpv54, hpv55; procede de diagnostic in vitro d'infections a papillomavirus et d'immunisation in vivo contre ces papillomavirus
US5559149A (en) 1990-01-29 1996-09-24 Johnson & Johnson Consumer Products, Inc. Skin care compositions containing retinoids
US5195965A (en) * 1991-03-07 1993-03-23 Shantha Totada R Method and apparatus for localized treatment of human viral infections and cancers
US5646186A (en) 1994-05-17 1997-07-08 Johnson & Johnson Consumer Products, Inc. Retinoid composition
US5409690A (en) * 1993-06-23 1995-04-25 Chemex Pharmaceuticals, Inc. Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol
US6365787B1 (en) * 1994-09-30 2002-04-02 The Johns Hopkins University Compounds for the suppression of HIV TAT transactivation
US6071949A (en) 1995-03-14 2000-06-06 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
US5837252A (en) * 1996-07-01 1998-11-17 Larreacorp, Ltd. Nontoxic extract of Larrea tridentata and method of making same
US5827898A (en) 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes
US6245523B1 (en) 1996-11-20 2001-06-12 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
US6214874B1 (en) * 1999-10-15 2001-04-10 John Hopkins University Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N
US6608108B2 (en) * 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives

Also Published As

Publication number Publication date
US5663209A (en) 1997-09-02
US6365787B1 (en) 2002-04-02
JP2006273869A (ja) 2006-10-12
DE69535804D1 (de) 2008-09-18
USRE40246E1 (en) 2008-04-15
AU700481B2 (en) 1999-01-07
EP0783474B1 (en) 2008-08-06
CA2200991C (en) 2007-07-10
CN1762951A (zh) 2006-04-26
EP0783474A1 (en) 1997-07-16
ES2312168T3 (es) 2009-02-16
JPH10509421A (ja) 1998-09-14
ATE403635T1 (de) 2008-08-15
US6291524B1 (en) 2001-09-18
AU3633995A (en) 1996-04-26
WO1996010549A1 (en) 1996-04-11
CN1211335C (zh) 2005-07-20
CN1162301A (zh) 1997-10-15
EP0783474A4 (enExample) 1997-08-27
CA2200991A1 (en) 1996-04-11
CN100413835C (zh) 2008-08-27

Similar Documents

Publication Publication Date Title
JP3966900B2 (ja) Ｈｉｖ・ｔａｔトランス活性化を抑制するための化合物
WO1996010549A9 (en) Compounds for the suppression of hiv tat transactivation
Gnabre et al. Isolation of anti-HIV-1 lignans from Larrea tridentata by counter-current chromatography
DE69507185T2 (de) Arzneimittel zur Behandlung von Osteoporose
KR101567633B1 (ko) 감귤 미성숙과 추출물, 또는 시네프린 또는 이의 염을 유효성분으로 포함하는 염증성 피부질환 치료 또는 예방용 조성물
Rasheed et al. Pharmacological influence of nutmeg and nutmeg constituents on rabbit platelet function
US6586021B2 (en) Method for extraction and purification of biologically useful molecules from a mangrove plant Salvadora persica L
KR100439425B1 (ko) 잔토리졸을 포함하는 조성물 및 그 용도
KR100191901B1 (ko) 새로운 세스퀴테르펜 에스테르 화합물
US20090142421A1 (en) Active fraction of a polar solvent extract from the latex of euphorbiaceae plants
US5989555A (en) Extracts of Larrea tridentata having antiviral activity and their use for treating viral infections
JP2003073292A (ja) 新規コレステロール合成阻害剤
EP1345884A1 (en) Anti-viral compounds
FR2882357A1 (fr) Utilisation de derives de phenanthrenes en tant qu'agents anti-inflammatoires, procede de synthese et produits intermediaires
HK1090023A (en) Compounds for the suppression of hiv tat transactivation
JPH07112931A (ja) エプスタイン−バーウイルス活性化抑制剤
AU2005202105B2 (en) Biologically active aqueous fraction of an extract obtained from a mangrove plant Salvadora Persica L.
KR0131512B1 (ko) 청피로부터 분리한 우울증 치료제
KR100396526B1 (ko) 잔토리졸을 포함하는 항염증 조성물
JPH02243631A (ja) 抗発癌プロモーター
CN101257912A (zh) 大戟科植物乳汁的极性溶剂提取物的活性级份
JPH0131509B2 (enExample)
JP2003277257A (ja) 発癌予防剤
JPH02300128A (ja) ビスデチオジメチルチオアセチルアポアラノチンを有効成分とする血小板凝集阻害剤
IE20011021U1 (en) Anti-viral compounds

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20040216

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20040216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060331

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20070508

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20070530

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110608

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120608

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120608

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130608

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term